Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated lung cancer or breast cancer and also showed clinical benefit when combined with chemotherapy as first-line treatment of lung cancer or breast cancer (78, 79). This evidence concerns the gene CD274 and breast carcinoma.